Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00137111 · OUTCOME

Continuous Complete Remission Since Week 56 Therapy.

Therapy for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia · Source last updated 2020-09-11

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
NUMBER
Unit
Percentage of participants
Interval / dispersion
Not reported
Time frame
Median follow up time (range) 4.5 (1 to 7.8) years

What was measured

CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate.

Analysis population: Patients meeting the following high risk CNS Relapse criteria: white cell blood cell count at diagnosis more than 100,000; Philadelphia Chromosome Positive; CNS 3 at diagnosis; T-Lineage with white blood cell count more than 50,000.

Groups in this outcome

Patients With High Risk of CNS Relapse

This is a subset of all patients enrolled. It is not a specific treatment arm.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Patients With High Risk of CNS Relapse70

Reported measurements

Source class 1
Values in Percentage of participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Patients With High Risk of CNS Relapse92.2Not reported82100Not reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        lower Limit
        82
        upper Limit
        100
        value
        92.2
denoms
  1. counts
    1. group Id
      OG000
      value
      70
    units
    Participants
description
CCR was measured from end of week 56 therapy to the date of first treatment failure of any kind (relapse, death, lineage switch, or second malignancy) or to the last date of follow-up. Measurement was determined by Kaplan-Meyer estimate.
groups
  1. description
    This is a subset of all patients enrolled. It is not a specific treatment arm.
    id
    OG000
    title
    Patients With High Risk of CNS Relapse
param Type
NUMBER
population Description
Patients meeting the following high risk CNS Relapse criteria: white cell blood cell count at diagnosis more than 100,000; Philadelphia Chromosome Positive; CNS 3 at diagnosis; T-Lineage with white blood cell count more than 50,000.
reporting Status
POSTED
time Frame
Median follow up time (range) 4.5 (1 to 7.8) years
title
Continuous Complete Remission Since Week 56 Therapy.
type
PRIMARY
unit Of Measure
Percentage of participants

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice